Testing ABP-671 for gout risk in chronic kidney disease
Part of Kidney & urinary, Women’s health & pregnancy clinical trials.
This study tests if a new drug, ABP-671, can safely lower high uric acid levels in people with chronic kidney disease. It may help reduce gout attacks and kidney damage.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old
- You have been diagnosed with chronic kidney disease (CKD)
- Your uric acid level is above 7.0 mg/dL
- You have a BMI between 18.0 and 40.0
- You have not had a kidney transplant
- Your liver function tests are within 3 times the normal range
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine, IG3018, to lower high uric acid levels in people with or without chronic kidney disease. It aims to find the right dose and see if it's safe.
This study tests how a new drug, ABP-671, interacts with allopurinol (a common gout medicine) in people with gout. It is looking for participants with normal or moderately reduced kidney function.
This trial tests a new tablet called BR2251 for people with gout and high uric acid. It aims to lower uric acid levels and manage gout symptoms.
This trial tests an experimental tablet (SHR4640) added to the standard gout medicine febuxostat (40 mg daily) for people whose uric acid remains too high despite febuxostat alone. The goal is to see if the combination lowers uric acid more effectively and safely.
This trial tests a new tablet (HR091506) for adults with gout and high uric acid. It aims to lower uric acid levels and reduce gout attacks, especially for people with more severe gout (like tophi or frequent attacks).
This trial tests a new medication, ABP-745, for people having an acute gout flare. It aims to see if the drug is safe and helps reduce pain and inflammation.
Hear when a new Chronic kidney disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.